Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The involvement of B cells, complement activation and subsequent immune complex deposition has all been implicated in the pathogenesis of rheumatoid arthritis (RA). Although the reduced expression of complement receptor 1 (CR1, CD35) and 2 (CR2, CD21) on the B cells of RA patients has been known for a long time, their exact role in B-cell tolerance and autoimmunity is not yet fully understood. To get a deeper insight into the possible mechanisms, we studied the expression and function of CR1 and CR2 on various subsets of B cells of healthy donors and RA patients at various stages of the disease by FACS analysis, (3)H-thymidine incorporation and ELISA. We found that CD19(+)CD27(-) naive B cells up-regulate the expression of the inhibitory CR1 during differentiation to CD19(+)CD27(+) memory B cells both in healthy donors and in RA patients, whereas the expression of the activatory CR2 is down-regulated. This clearly demonstrates that the expression of these two antagonistic complement receptors is regulated differentially during the development of human B cells, a phenomenon which may influence the maintenance of peripheral B-cell tolerance. Our functional studies show that after clustering CR1 both by its natural ligand and To5 mAb, the inhibitory function of CD35 is maintained in RA patients, despite its significantly reduced expression compared with healthy individuals. Besides blocking B-cell receptor-induced proliferation, CR1 inhibits the differentiation of B cells to plasmablasts and their immunoglobulin production. Since the reduced expression of CR1 in RA patients does not affect its inhibitory function, this receptor might serve as a new target for therapeutical interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fcγ receptors as regulators of immune responses
Nimmerjahn, F., & Ravetch, J. V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2206 · Cited by 2,947
Complement and its role in innate and adaptive immune responses
Dunkelberger, J. R., & Song, W.-C. (2010) · Cell Research · doi:10.1038/cr.2009.139 · Cited by 1,932
C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
Dempsey, P. W., Allison, M. E. D., Akkaraju, S., Goodnow, C. C., & Fearon, D. T. (1996) · Science · doi:10.1126/science.271.5247.348 · Cited by 1,197
Cited by
Overview of complement activation and regulation
Noris, M., & Remuzzi, G. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.001 · Cited by 864
Production of complement components by cells of the immune system
Lubbers, R., van Essen, M. F., van Kooten, C., & Trouw, L. A. (2017) · Clinical and Experimental Immunology · doi:10.1111/cei.12952 · Cited by 480
Complement as a regulator of adaptive immunity
Killick, J., Morisse, G., Sieger, D., & Astier, A. L. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-017-0644-y · Cited by 129
“Reduced expression of CD35 in a number of autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus (SLE) has been obsvered, although whether these reduced levels contribute to disease remains to be firmly established [96].”
Background
Metadata
- Authors
- Kremlitzka, M., Polgar, A., Fulop, L., Kiss, E., Poor, G., & Erdei, A.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-07
- Volume
- 25
- Issue
- 1
- Pages
- 25-33
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2158313944
- Cited by
- 52
- References
- 3
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. https://app.cochat.ai/papers/10.1093/intimm/dxs090
- The paper
- Kremlitzka, M., Polgar, A., Fulop, L., Kiss, E., Poor, G., & Erdei, A. (2013). Complement receptor type 1 (CR1, CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. International Immunology. https://doi.org/10.1093/intimm/dxs090
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.